Eurofins Expands Its Footprint in Environment Testing with the Acquisition of Ana Laboratories, Inc. in the USA
July 05 2017 - 12:30AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a global leader in
environment testing, announces that it has acquired Ana
Laboratories, Inc. (“ANA”), one of the largest laboratory networks
specialized in fluid and tribology analyses serving the public mass
transit sector in the USA.
Over the last 40 years, ANA has become one of the most trusted
laboratory partners for fluid analysis for the transport sector in
the country. The company employs 48 staff in 7 laboratories serving
75 of the largest city transit agencies (such as the New York City
Transit), several statewide Departments of Transportation including
Texas and Connecticut, as well as the largest railway companies
nationwide. This acquisition therefore expands Eurofins’
environment testing footprint into industrial fluid analysis in the
US. Given ANA’s penetration of the public mass transit sector,
Eurofins believes it represents a solid entry platform into
industrial oil testing, as well as the wider market for tribology
analysis.
For more information, please visit
www.eurofins.com.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170704005100/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024